Item 2. Properties
ITEM 2. PROPERTIES
The Company owns the facilities that its headquarters and R&D Systems subsidiary occupy in Minneapolis, Minnesota. The Minneapolis facilities are utilized by both the Company’s Protein Sciences and Diagnostics and Genomics segments.
The Minneapolis complex includes approximately 800,000 square feet of space in several adjoining buildings. Bio-Techne uses approximately 710,000 square feet of the complex for administrative, research, manufacturing, shipping and warehousing activities. The Company is currently leasing the remaining space in the complex as retail and office space. The Company also owns a 61,000 square foot facility in Saint Paul, Minnesota that is utilized for additional manufacturing capabilities and activities.
The Company also owns a 34,000 square foot manufacturing facility in Flowery Branch, Georgia. This facility is utilized by the Company’s Protein Sciences segment.
The Company owns a 16,000 square foot facility that its Bio-Techne Europe subsidiary occupies in Abingdon, England. This facility is utilized by the Company’s Protein Sciences and Diagnostics and Genomics segments.
The Company owns a 9,000 square foot facility that its Canada subsidiaries occupy in Toronto, Canada. This facility is utilized by the Company’s Protein Sciences segment.
The Company owns a 52,700 square foot manufacturing facility in Wallingford, Connecticut. This facility is utilized by the Company’s Protein Sciences segment.
The Company leases the following material facilities, which are utilized by both the Company’s Protein Sciences segment the Diagnostics & Genomics segment. Certain locations are not named because they were not significant individually or in the aggregate as of the date of this report.
Subsidiary
Location
Type
Square Feet
Bio-Techne Ltd
Langley, United Kingdom
Warehouse
12,000
Bio-Techne China
Shanghai and Beijing, China
Office/warehouse
29,200
Tocris
Bristol, United Kingdom
Office/manufacturing/lab/warehouse
30,000
PrimeGene
Shanghai, China
Office/manufacturing/lab
79,900
Bionostics
Devens, Massachusetts
Office/manufacturing
70,000
Novus Biologicals
Centennial, Colorado
Office/warehouse
74,000
ProteinSimple
San Jose, California
Office/manufacturing/warehouse
98,000
ProteinSimple Ltd.
Ottawa, Canada
Office/manufacturing/warehouse
10,800
CyVek
Wallingford, Connecticut
Office/manufacturing/warehouse
22,700
Cliniqa
San Marcos, California
Office/manufacturing/warehouse
62,800
Advanced Cell Diagnostics
Newark, California
Office/manufacturing/warehouse
55,900
Bio-Techne France
Rennes, France
Office/warehouse
11,000
Exosome Diagnostics
Waltham, Massachusetts
Office/manufacturing/warehouse
38,400
R&D Systems
Minneapolis, Minnesota
Office/manufacturing/warehouse
10,700
Asuragen
Austin, Texas
Office/manufacturing/warehouse
47,400
Bio-Techne Ireland
Dublin, Ireland
Warehouse
25,000
ITEM 3. LEGAL PROCEEDINGS
As of August 18, 2023, the Company is not a party to any legal proceedings that, individually or in the aggregate, are reasonably expected to have a material adverse effect on the Company’s business, results of operations, financial condition or cash flows.
30
Table of Contents
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
PART II